These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27227839)

  • 41. Antibiotics in the clinical pipeline in 2011.
    Butler MS; Cooper MA
    J Antibiot (Tokyo); 2011 Jun; 64(6):413-25. PubMed ID: 21587262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Microbiological findings from the Haiti disaster.
    Marra AR; Valle Martino MD; Ribas MR; Rodriguez-Taveras C; Pavao Dos Santos OF
    Travel Med Infect Dis; 2012 May; 10(3):157-61. PubMed ID: 22521601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008-2013 at a tertiary hospital in Shanghai, China.
    Guo W; He Q; Wang Z; Wei M; Yang Z; Du Y; Wu C; He J
    Am J Infect Control; 2015 Apr; 43(4):358-64. PubMed ID: 25838134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Creative targeting of the Gram-negative outer membrane in antibiotic discovery.
    MacNair CR; Tsai CN; Brown ED
    Ann N Y Acad Sci; 2020 Jan; 1459(1):69-85. PubMed ID: 31762048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Essential oils from Moroccan plants as potential chemosensitisers restoring antibiotic activity in resistant Gram-negative bacteria.
    Fadli M; Chevalier J; Saad A; Mezrioui NE; Hassani L; Pages JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):325-30. PubMed ID: 21752605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibacterial and antibiotic resistance modulatory activities of leaves and bark extracts of Recinodindron heudelotii (Euphorbiaceae) against multidrug-resistant Gram-negative bacteria.
    Fankam AG; Kuiate JR; Kuete V
    BMC Complement Altern Med; 2017 Mar; 17(1):168. PubMed ID: 28340621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tackling Threats and Future Problems of Multidrug-Resistant Bacteria.
    Medina E; Pieper DH
    Curr Top Microbiol Immunol; 2016; 398():3-33. PubMed ID: 27406189
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?
    Page MG; Bush K
    Curr Opin Pharmacol; 2014 Oct; 18():91-7. PubMed ID: 25277839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multidrug-resistant Gram-negative bacteria in postoperative infections.
    Singh AV; Mishra B; Thakur A
    J Indian Med Assoc; 2009 Mar; 107(3):148-50, 163. PubMed ID: 19810380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current problematic and emergence of carbapenemase-producing bacteria: a brief report from a Libyan hospital.
    Elramalli A; Almshawt N; Ahmed MO
    Pan Afr Med J; 2017; 26():180. PubMed ID: 28674573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity.
    Rabanal F; Grau-Campistany A; Vila-Farrés X; Gonzalez-Linares J; Borràs M; Vila J; Manresa A; Cajal Y
    Sci Rep; 2015 May; 5():10558. PubMed ID: 26024044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin.
    Personne Y; Curtis MA; Wareham DW; Waite RD
    J Antimicrob Chemother; 2014 Dec; 69(12):3236-43. PubMed ID: 25134721
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and anti-bacterial activity of some heterocyclic chalcone derivatives bearing thiofuran, furan, and quinoline moieties.
    Zheng CJ; Jiang SM; Chen ZH; Ye BJ; Piao HR
    Arch Pharm (Weinheim); 2011 Oct; 344(10):689-95. PubMed ID: 21887800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients.
    Cohen J
    J Antimicrob Chemother; 2013 Mar; 68(3):490-1. PubMed ID: 23152481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and antimicrobial activity of small cationic amphipathic aminobenzamide marine natural product mimics and evaluation of relevance against clinical isolates including ESBL-CARBA producing multi-resistant bacteria.
    Igumnova EM; Mishchenko E; Haug T; Blencke HM; Sollid JUE; Fredheim EGA; Lauksund S; Stensvåg K; Strøm MB
    Bioorg Med Chem; 2016 Nov; 24(22):5884-5894. PubMed ID: 27692769
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibiotic Trends Amid Multidrug-Resistant Gram-Negative Infections in Intensive Care Units.
    Fowler LH; Lee S
    Crit Care Nurs Clin North Am; 2017 Mar; 29(1):111-118. PubMed ID: 28160952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.
    McGowan JE
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S29-37; discussion S64-73. PubMed ID: 16813979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens.
    Saha S; Savage PB; Bal M
    J Appl Microbiol; 2008 Sep; 105(3):822-8. PubMed ID: 18452533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of topical antimicrobial agents against multidrug-resistant bacteria recovered from burn patients.
    Glasser JS; Guymon CH; Mende K; Wolf SE; Hospenthal DR; Murray CK
    Burns; 2010 Dec; 36(8):1172-84. PubMed ID: 20542641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.